AnaptysBio, Inc.’s Imsidolimab Performs Well in Phase 3 GPP Study
Generalized pustular psoriasis (GPP) patients who responded to AnaptysBio, Inc.’s investigational imsidolimab (IL-36R mAb) in GEMINI-1 and moved into GEMINI-2 maintained clear or almost clear skin through at Week 24, according to topline results reported by the Company. In the 45-patient GEMINI-1 Phase 3 trial, patients were randomized 1:1:1 to receive a single infusion of […]